Payment overview · 2025
General Payments
$15.92
1 reported records · 1 companies
Healthcare provider profile · identity verified
Lisa Melsky, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WAYNE, NJ · NPI 1609950906
Verified facts
What the public records show
CMS Open Payments records show Lisa Melsky, MD received $15.92 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.92 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $15.92 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 46 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 521 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 86 |
| Metformin Hcl | Metformin Hcl | 305 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 79 |
| Losartan Potassium | Losartan Potassium | 243 | 69 |
| Prednisone | Prednisone | 231 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 55 |
| Alprazolam | Alprazolam | 190 | 42 |
| Omeprazole | Omeprazole | 179 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 43 |
| Azithromycin | Azithromycin | 155 | 107 |
| Simvastatin | Simvastatin | 148 | 33 |
| Eliquis | Apixaban | 139 | 23 |
| Meloxicam | Meloxicam | 139 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 129 | 37 |
| Cefuroxime | Cefuroxime Axetil | 118 | 89 |
| Januvia | Sitagliptin Phosphate | 113 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 43 |
| Ezetimibe | Ezetimibe | 108 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 24 |
| Sertraline Hcl | Sertraline Hcl | 100 | 30 |
| Gabapentin | Gabapentin | 98 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 21 |
| Vascepa | Icosapent Ethyl | 92 | 14 |
| Zenpep | Lipase/Protease/Amylase | 88 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 37 |
| Valsartan | Valsartan | 83 | 18 |
| Glimepiride | Glimepiride | 81 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 80 | 14 |
| Lisinopril | Lisinopril | 80 | 23 |
| Furosemide | Furosemide | 72 | 18 |
| Allopurinol | Allopurinol | 71 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 27 |
| Telmisartan | Telmisartan | 70 | 15 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Synthroid | Levothyroxine Sodium | 64 | 15 |
| Carvedilol | Carvedilol | 61 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 11 |
| Mupirocin | Mupirocin | 60 | 40 |
| Meclizine Hcl | Meclizine Hcl | 58 | 15 |
| Linzess | Linaclotide | 57 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 48 |
| Ozempic | Semaglutide | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Atenolol | Atenolol | 49 | 12 |
| Valacyclovir | Valacyclovir Hcl | 49 | 22 |
| Irbesartan | Irbesartan | 48 | 11 |
| Creon | Lipase/Protease/Amylase | 46 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 12 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Famotidine | Famotidine | 33 | 14 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Edarbi | Azilsartan Medoxomil | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Torsemide | Torsemide | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 19 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | 18 |
| Nystatin | Nystatin | 20 | suppressed |
| Toprol Xl | Metoprolol Succinate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lipitor | Atorvastatin Calcium | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Celebrex | Celecoxib | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Restasis | Cyclosporine | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.92 · 1 records | ABBVIE INC. | CREON, LINZESS | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error